A single dose of the ChAdOx2 RabG adenovirus-vectored rabies vaccine was safe and produced antibody levels above the protective threshold one year later in Tanzanian adults and children.

Is it true that a single dose of the ChAdOx2 RabG adenovirus-vectored rabies vaccine was safe and produced antibody levels above the protective threshold one year later in Tanzanian adults and children?

Unclear. The retrieved items include a trial report excerpt confirming durable immunogenicity of ChAdOx2 RabG in Tanzanian adults and children, plus earlier-stage ChAdOx2 RabG work in UK adults and mice. None of the placed items supplies the full picture of safety and one-year antibody levels above the protective threshold in Tanzanian adults and children.

Verdict: PARTIAL LEAN · 3 sources for, 0 against · Last checked 2 Oct 2026

The private library was unavailable for some searches in this check. Missing library results are not evidence against the claim.

Safety and immunogenicity of a single-dose adenovirus-vectored rabies vaccine over 1 year in adults and children in Tanzania: interim data from an ongoing, partly randomised, controlled, phase 1b/2 trial - PMC Lock. (n.d.). pmc.ncbi.nlm.nih.gov. https://doi.org/10.1016/S1473-3099(26)00071-X

Safety and immunogenicity of a candidate rabies vaccine (RAB001) - Health Research AuthorityHRA Health Research Authority. (n.d.). hra.nhs.uk. https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/safety-and-immunogenicity-of-a-candidate-rabies-vaccine-rab001/

Wang, C., Dulal, P., Zhou, X., Xiang, Z., Goharriz, H., Banyard, A., Green, N., Brunner, L., Ventura, R., Collin, N., Draper, S. J., Hill, A. V., Ashfield, R., Fooks, A. R., Ertl, H. C., & Douglas, A. D. (2018). A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis. doi.org. https://doi.org/10.1101/408013